These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
292 related items for PubMed ID: 8212826
1. Immune sera to individual Borrelia burgdorferi isolates or recombinant OspA thereof protect SCID mice against infection with homologous strains but only partially or not at all against those of different OspA/OspB genotype. Schaible UE, Wallich R, Kramer MD, Gern L, Anderson JF, Museteanu C, Simon MM. Vaccine; 1993; 11(10):1049-54. PubMed ID: 8212826 [Abstract] [Full Text] [Related]
2. Inhibition of Borrelia burgdorferi-tick interactions in vivo by outer surface protein A antibody. Pal U, Montgomery RR, Lusitani D, Voet P, Weynants V, Malawista SE, Lobet Y, Fikrig E. J Immunol; 2001 Jun 15; 166(12):7398-403. PubMed ID: 11390491 [Abstract] [Full Text] [Related]
6. Abilities of OspA proteins from different seroprotective groups of Borrelia burgdorferi to protect hamsters from infection. Lovrich SD, Callister SM, DuChateau BK, Lim LC, Winfrey J, Day SP, Schell RF. Infect Immun; 1995 Jun 15; 63(6):2113-9. PubMed ID: 7768589 [Abstract] [Full Text] [Related]
12. DNA vaccines expressing a fusion product of outer surface proteins A and C from Borrelia burgdorferi induce protective antibodies suitable for prophylaxis but Not for resolution of Lyme disease. Wallich R, Siebers A, Jahraus O, Brenner C, Stehle T, Simon MM. Infect Immun; 2001 Apr 15; 69(4):2130-6. PubMed ID: 11254567 [Abstract] [Full Text] [Related]
14. Lyme borreliosis in transgenic mice tolerant to Borrelia burgdorferi OspA or B. Fikrig E, Tao H, Chen M, Barthold SW, Flavell RA. J Clin Invest; 1995 Oct 15; 96(4):1706-14. PubMed ID: 7560061 [Abstract] [Full Text] [Related]
15. Vaccination against Lyme disease caused by diverse Borrelia burgdorferi. Fikrig E, Telford SR, Wallich R, Chen M, Lobet Y, Matuschka FR, Kimsey RB, Kantor FS, Barthold SW, Spielman A, Flavell RA. J Exp Med; 1995 Jan 01; 181(1):215-21. PubMed ID: 7807004 [Abstract] [Full Text] [Related]
16. The Lyme disease vaccine candidate outer surface protein A (OspA) in a formulation compatible with human use protects mice against natural tick transmission of B. burgdorferi. Golde WT, Burkot TR, Piesman J, Dolan MC, Capiau C, Hauser P, Dequesne G, Lobet Y. Vaccine; 1995 Apr 01; 13(5):435-41. PubMed ID: 7639011 [Abstract] [Full Text] [Related]
17. Immunization with outer surface protein (Osp) A, but not OspC, provides cross-protection of mice challenged with North American isolates of Borrelia burgdorferi. Probert WS, Crawford M, Cadiz RB, LeFebvre RB. J Infect Dis; 1997 Feb 01; 175(2):400-5. PubMed ID: 9203661 [Abstract] [Full Text] [Related]
18. Borrelia burgdorferi outer surface protein (osp) B expression independent of ospA. Liang FT, Caimano MJ, Radolf JD, Fikrig E. Microb Pathog; 2004 Jul 01; 37(1):35-40. PubMed ID: 15194158 [Abstract] [Full Text] [Related]
19. A recombinant vaccine for Lyme disease. Wallich R, Kramer MD, Simon MM. Behring Inst Mitt; 1994 Dec 01; (95):106-8. PubMed ID: 7755503 [Abstract] [Full Text] [Related]
20. Oral delivery of purified lipoprotein OspA protects mice from systemic infection with Borrelia burgdorferi. Luke CJ, Huebner RC, Kasmiersky V, Barbour AG. Vaccine; 1997 Dec 01; 15(6-7):739-46. PubMed ID: 9178476 [Abstract] [Full Text] [Related] Page: [Next] [New Search]